Lorazepam kinetics in the elderly

Clinical Pharmacology and Therapeutics
D J GreenblattR I Shader

Abstract

Lorazepam is a 3-hydroxy-1,4-benzodiazepine derivative biotransformed by glucuronide conjugation, followed by urinary excretion of the glucuronide metabolite. The kinetic properties of single 1.5- to 3.0-mg doses of intravenous lorazepam were assessed in 15 healthy elderly subjects, 60 to 84 yr of age, and in 15 healthy young subjects, 19 to 38 yr of age. Volumes of distribution for lorazepam in the elderly group (mean, 0.99 1/kg), were slightly but significantly smaller than in the young group (1.11 1/kg), suggesting less extensive drug distribution in the elderly. Values of elimination half-life (t1/2beta) in the elderly (15.9 hr) did not differ significantly from those in the young group (14.1 hr), but total clearance in the elderly (0.77 ml/min/kg) was 22% less (p less than 0.05) than in the young subjects (0.99 ml/min/kg). Age differences in lorazepam clearance were partly explained by more frequent cigarette smoking in the young subjects. Gender had no apparent relationship to kinetics. The rate and completeness of absorption of intramuscular (IM) and oral loraxepam was assessed in 10 of the elderly subjects. Deltoid IM injection and oral administration of tablets in the fasting state led to rapid absorption of lorazepam ...Continue Reading

References

Jan 1, 1983·Journal of Chronic Diseases·F Sjöqvist, G Alván
Jan 1, 1988·Pharmacology & Therapeutics·J Roberts, N Tumer
Jan 1, 1991·Pharmacology & Therapeutics·J O Miners, P I Mackenzie
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·T R Norman, G D Burrows
Oct 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·M KamimuraT Takeshita
May 21, 1998·Pharmacology & Therapeutics·L J Willmore
Nov 7, 2001·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J L DorneA G Renwick
Jun 25, 1999·Progress in Neurobiology·P GareriG De Sarro
Jun 1, 1991·British Journal of Clinical Pharmacology·J SonneF Andreasen
Sep 7, 2000·Journal of Clinical Pharmacology·G HochhausH Derendorf
Nov 1, 1981·Journal of Clinical Pharmacology·H G GilesE M Sellers
Mar 22, 2003·Acta Anaesthesiologica Scandinavica·H PleymO Dale
Oct 1, 1989·Journal of Clinical Pharmacology·D J GreenblattJ S Harmatz
Jan 1, 1989·Journal of Clinical Pharmacology·R E GammansJ A LaBudde
Aug 1, 1985·British Journal of Clinical Pharmacology·C G SwiftJ Robinson
Jan 1, 1986·Acta Psychiatrica Scandinavica. Supplementum·P J Cook
Jan 1, 1988·European Journal of Clinical Pharmacology·J O MinersD J Birkett
Aug 1, 1986·Arthritis and Rheumatism·D J GreenblattR I Shader
Jan 1, 1985·European Journal of Clinical Pharmacology·K H MolzP Philipp
Mar 1, 1985·British Journal of Clinical Pharmacology·D J GreenblattR I Shader
Apr 1, 1984·Australian and New Zealand Journal of Medicine·P C Ho, E J Triggs
Jan 1, 1981·British Journal of Clinical Pharmacology·R I Shader, D J Greenblatt
Jan 1, 1984·Current Medical Research and Opinion·R BanderaS Garattini
Jan 1, 1981·European Journal of Clinical Pharmacology·T R NormanK P Maguire
Jan 1, 1983·Drug Metabolism Reviews·E M SellersM K Romach
Mar 1, 1983·British Journal of Clinical Pharmacology·R JochemsenD D Breimer
Nov 1, 1982·Journal of the American Geriatrics Society·D J GreenblattR I Shader
Apr 11, 2008·Clinical Pharmacokinetics·Jennifer M Butler, Evan J Begg
Jul 1, 1992·Biopharmaceutics & Drug Disposition·K Woodhouse
Jan 1, 1986·European Journal of Clinical Pharmacology·H GhabrialM L Mashford
Nov 1, 1983·British Journal of Clinical Pharmacology·J O MinersD J Birkett
Jan 1, 1984·Current Medical Research and Opinion·D R AbernethyR I Shader
Jan 1, 1996·Epilepsia·L J Willmore
Apr 1, 1982·Journal of the American Geriatrics Society·M DivollD J Greenblatt
Sep 1, 1987·British Journal of Clinical Pharmacology·A RakhitR Williams
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S Arroyo, G Kramer
Aug 23, 2006·Expert Opinion on Drug Metabolism & Toxicology·Klaus Turnheim
Jun 16, 2011·British Journal of Clinical Pharmacology·Paul K L ChinEvan J Begg
Jan 1, 1987·Journal of Psychopharmacology·R J AncillJ S Kennedy
Apr 1, 1989·Journal of Clinical Pharmacology·O Grech-BélangerM Blouin
Jan 1, 1983·Drug Metabolism Reviews·D J GreenblattR I Shader
Mar 1, 1982·British Journal of Clinical Pharmacology·R JochemsenD D Breimer

Related Concepts

Conjugation
Intravenous
Body of First Thoracic Vertebra
Anti-Anxiety Effect
Entire Deltoid Muscle
Bz-423
Process of Absorption
Lorazepam
Senility
Intramuscular

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.

Related Papers

Clinical Pharmacology and Therapeutics
D R StanskiE Lowenstein
The Journal of Pharmacology and Experimental Therapeutics
D J GreenblattR I Shader
© 2020 Meta ULC. All rights reserved